Curated News
By: NewsRamp Editorial Staff
April 07, 2026
Catalyst Crew Launches PulmoAI: AI Platform for Lung Disease Detection
TLDR
- Catalyst Crew Technologies' PulmoAI offers early detection of pulmonary diseases, giving healthcare providers a competitive edge in diagnostics and expanding market opportunities in Latin America.
- PulmoAI integrates CT scans, X-rays, and biomarkers using AI to analyze respiratory data, detect abnormalities, and predict disease progression for clinical review.
- This AI platform improves healthcare access in emerging markets, enabling earlier diagnosis of lung conditions and potentially saving lives through technology-driven solutions.
- An AI system that reads chest scans and predicts lung disease progression could revolutionize how respiratory health is monitored in remote areas.
Impact - Why it Matters
This development matters because pulmonary diseases, including chronic conditions like COPD and acute issues like pneumonia, represent a significant global health burden, particularly in emerging markets with limited diagnostic resources. AI-powered tools like PulmoAI could democratize access to advanced respiratory diagnostics, enabling earlier detection and intervention, which is crucial for improving patient outcomes and reducing healthcare costs. By focusing on Latin America, where healthcare disparities are pronounced, this technology has the potential to address critical gaps in specialized care, supporting healthcare providers in making data-driven decisions and enhancing overall system efficiency. As AI continues to transform medicine, innovations like this highlight how technology can bridge accessibility gaps, ultimately leading to better public health outcomes and more equitable healthcare delivery worldwide.
Summary
Catalyst Crew Technologies Corp. (OTC: CCTC), a digital health and artificial intelligence technology company, has announced the development of PulmoAI, an innovative AI-powered module designed to revolutionize pulmonary disease detection and predictive analysis. This specialized tool aims to assist healthcare providers by analyzing respiratory health data through artificial intelligence-driven analytics, with capabilities including automated interpretation of thoracic imaging like CT scans and chest X-rays, detection of pulmonary abnormalities, and predictive modeling of disease progression. The platform integrates multiple data inputs—including pulmonary function tests and inflammatory biomarkers—to generate structured outputs that support clinical review and care coordination, positioning it as a key component within Catalyst Crew's broader digital health ecosystem for scalable deployment across telehealth services and remote diagnostics.
Under the leadership of CEO Dr. Kevin Rodan Levy, the company emphasizes PulmoAI's potential to enhance how healthcare providers detect and monitor pulmonary conditions, particularly in environments with limited access to specialized diagnostics. Catalyst Crew Technologies intends to prioritize market development in Latin America, where AI-enabled healthcare technologies could expand access to respiratory diagnostics, support earlier identification of conditions, and improve healthcare system efficiency. The development reflects the company's strategic transition into AI-enabled healthcare, with plans to integrate PulmoAI across existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform, while evaluating opportunities for pilot programs and strategic partnerships.
For more information, stakeholders can visit the company's website or review filings with the U.S. Securities and Exchange Commission, as highlighted in the original release on www.newmediawire.com. This announcement underscores Catalyst Crew's commitment to building scalable, technology-driven solutions that address the growing demand for modernized healthcare delivery systems in emerging markets, though the company notes it is a development-stage enterprise with forward-looking statements subject to risks and uncertainties.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Catalyst Crew Launches PulmoAI: AI Platform for Lung Disease Detection
